EQS Group-Media / 2019-10-29 / 19:00
*Media Release*
*Medacta Announces First Surgery with MectaLock PEEK in Australia*
_CASTEL SAN PIETRO_, _29 October 2019_ - Medacta today announced the
successful completion of the first surgery utilizing its MectaLock PEEK
Suture Anchor for labral repair, following approval from Australia's
Therapeutic Goods Administration (TGA).
The MectaLock PEEK Suture Anchor is one of Medacta's most recent sports
medicine offerings. With a complete and comprehensive portfolio to
accommodate different patient anatomies and surgeon preferences, the
MectaLock PEEK is an implantable device used for soft tissue re-fixation in
acetabular labral repairs in the hip and glenoid labrum repairs in the
shoulder.
Parminder J. Singh, M.D., performed the first hip labral repair surgery
using the MectaLock PEEK at St. Vincent's Private Hospital East Melbourne in
Australia on October 25. "I am thankful to Medacta for allowing me to be
part of a world-class hip arthroscopy surgeons group. Medacta engineers have
listened to our requirements and have worked hard to develop effective
solutions which can benefit patients from around the world," said Dr. Singh.
With the MectaLock PEEK Suture Anchor, Medacta has added an innovative
knotless instability anchor to its Sports Medicine portfolio. "Thanks to the
shorter anchor body and reduced drill depth requirement, this new product is
bone preserving and can be beneficial in instability repairs," said
Francesco Siccardi, CEO of Medacta International. "This surgery is a further
important milestone for Medacta's nascent Sports Medicine division, and we
look forward to rolling out this product throughout Australia and
worldwide."
*Contact*
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch
*About Medacta*
Medacta is an international company specializing in the design and
production of innovative orthopaedic products and the development of
accompanying surgical techniques for joint replacement, spine surgery, and
sports medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS")
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated "MySolutions" technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
Issuer: Medacta Group SA
Key word(s): Advertisement/Communication
End of Corporate News
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 899573
End of News EQS Group Media
899573 2019-10-29
(END) Dow Jones Newswires
October 29, 2019 14:00 ET (18:00 GMT)
